Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Parallel Group Insulin Inhalation vs Subcutaneous Human Insulin in Type 2 Diabetes
2005-005381-37Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of insulin human in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Acceptance of insulin therapy. Started Jun 2006; status: terminated.
02
Drugs
insulin human
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-005381-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005381-37.